BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 29535836)

  • 1. The absence of a novel intron 19-retaining
    Alshareef A; Irwin MS; Gupta N; Zhang HF; Haque M; Findlay SD; Seong BKA; Lai J; Rayis M; Al-Dandan S; Lai R
    Oncotarget; 2018 Feb; 9(12):10698-10713. PubMed ID: 29535836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intragenic anaplastic lymphoma kinase (ALK) rearrangements: translocations as a novel mechanism of ALK activation in neuroblastoma tumors.
    Fransson S; Hansson M; Ruuth K; Djos A; Berbegall A; Javanmardi N; Abrahamsson J; Palmer RH; Noguera R; Hallberg B; Kogner P; Martinsson T
    Genes Chromosomes Cancer; 2015 Feb; 54(2):99-109. PubMed ID: 25251827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of ALK, MYCN, and the ALK ligand ALKAL2 (FAM150B/AUGα) in neuroblastoma patient samples with chromosome arm 2p rearrangements.
    Javanmardi N; Fransson S; Djos A; Umapathy G; Östensson M; Milosevic J; Borenäs M; Hallberg B; Kogner P; Martinsson T; Palmer RH
    Genes Chromosomes Cancer; 2020 Jan; 59(1):50-57. PubMed ID: 31340081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical expression of anaplastic lymphoma kinase in neuroblastoma and its relations with some clinical and histopathological features.
    Phan TDA; Nguyen TQ; To NT; Thanh TL; Ngo DQ
    J Pathol Transl Med; 2024 Jan; 58(1):29-34. PubMed ID: 38229432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification.
    De Brouwer S; De Preter K; Kumps C; Zabrocki P; Porcu M; Westerhout EM; Lakeman A; Vandesompele J; Hoebeeck J; Van Maerken T; De Paepe A; Laureys G; Schulte JH; Schramm A; Van Den Broecke C; Vermeulen J; Van Roy N; Beiske K; Renard M; Noguera R; Delattre O; Janoueix-Lerosey I; Kogner P; Martinsson T; Nakagawara A; Ohira M; Caron H; Eggert A; Cools J; Versteeg R; Speleman F
    Clin Cancer Res; 2010 Sep; 16(17):4353-62. PubMed ID: 20719933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined Detection of Copy Number Variations of MYCN and ALK using Droplet Digital Polymerase Chain Reaction to Identify High-Risk Patients with Neuroblastoma.
    Trivedi T; Panchal K; Bhalala N; Trivedi P; Panchal H
    World Neurosurg; 2022 Mar; 159():e48-e57. PubMed ID: 34861448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New therapeutic strategies in neuroblastoma: combined targeting of a novel tyrosine kinase inhibitor and liposomal siRNAs against ALK.
    Di Paolo D; Yang D; Pastorino F; Emionite L; Cilli M; Daga A; Destafanis E; Di Fiore A; Piaggio F; Brignole C; Xu X; Liang C; Gibbons J; Ponzoni M; Perri P
    Oncotarget; 2015 Oct; 6(30):28774-89. PubMed ID: 26299615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using droplet digital PCR to analyze
    Lodrini M; Sprüssel A; Astrahantseff K; Tiburtius D; Konschak R; Lode HN; Fischer M; Keilholz U; Eggert A; Deubzer HE
    Oncotarget; 2017 Oct; 8(49):85234-85251. PubMed ID: 29156716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells.
    Schönherr C; Ruuth K; Kamaraj S; Wang CL; Yang HL; Combaret V; Djos A; Martinsson T; Christensen JG; Palmer RH; Hallberg B
    Oncogene; 2012 Dec; 31(50):5193-200. PubMed ID: 22286764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncogenic mutations of ALK kinase in neuroblastoma.
    Chen Y; Takita J; Choi YL; Kato M; Ohira M; Sanada M; Wang L; Soda M; Kikuchi A; Igarashi T; Nakagawara A; Hayashi Y; Mano H; Ogawa S
    Nature; 2008 Oct; 455(7215):971-4. PubMed ID: 18923524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation of conditional ALK F1174L mutant mouse models for the study of neuroblastoma pathogenesis.
    Ono S; Saito T; Terui K; Yoshida H; Enomoto H
    Genesis; 2019 Oct; 57(10):e23323. PubMed ID: 31218818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ALK amplification and protein expression predict inferior prognosis in neuroblastomas.
    Wang M; Zhou C; Sun Q; Cai R; Li Y; Wang D; Gong L
    Exp Mol Pathol; 2013 Oct; 95(2):124-30. PubMed ID: 23797004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aberrant activation of ALK kinase by a novel truncated form ALK protein in neuroblastoma.
    Okubo J; Takita J; Chen Y; Oki K; Nishimura R; Kato M; Sanada M; Hiwatari M; Hayashi Y; Igarashi T; Ogawa S
    Oncogene; 2012 Nov; 31(44):4667-76. PubMed ID: 22249260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of modified Shimada classification with MYCN and 1p36 status detected by fluorescence in situ hybridization in neuroblastoma.
    Altungoz O; Aygun N; Tumer S; Ozer E; Olgun N; Sakizli M
    Cancer Genet Cytogenet; 2007 Jan; 172(2):113-9. PubMed ID: 17213019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients.
    Passoni L; Longo L; Collini P; Coluccia AM; Bozzi F; Podda M; Gregorio A; Gambini C; Garaventa A; Pistoia V; Del Grosso F; Tonini GP; Cheng M; Gambacorti-Passerini C; Anichini A; Fossati-Bellani F; Di Nicola M; Luksch R
    Cancer Res; 2009 Sep; 69(18):7338-46. PubMed ID: 19723661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical feature of anaplastic lymphoma kinase-mutated neuroblastoma.
    Ogura T; Hiyama E; Kamei N; Kamimatsuse A; Ueda Y; Ogura K
    J Pediatr Surg; 2012 Oct; 47(10):1789-96. PubMed ID: 23084186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted expression of mutated ALK induces neuroblastoma in transgenic mice.
    Heukamp LC; Thor T; Schramm A; De Preter K; Kumps C; De Wilde B; Odersky A; Peifer M; Lindner S; Spruessel A; Pattyn F; Mestdagh P; Menten B; Kuhfittig-Kulle S; Künkele A; König K; Meder L; Chatterjee S; Ullrich RT; Schulte S; Vandesompele J; Speleman F; Büttner R; Eggert A; Schulte JH
    Sci Transl Med; 2012 Jul; 4(141):141ra91. PubMed ID: 22764207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic abnormalities in adolescents and young adults with neuroblastoma: A report from the Italian Neuroblastoma group.
    Mazzocco K; Defferrari R; Sementa AR; Garaventa A; Longo L; De Mariano M; Esposito MR; Negri F; Ircolò D; Viscardi E; Luksch R; D'Angelo P; Prete A; Castellano A; Massirio P; Erminio G; Gigliotti AR; Tonini GP; Conte M
    Pediatr Blood Cancer; 2015 Oct; 62(10):1725-32. PubMed ID: 25925003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BLM germline and somatic PKMYT1 and AHCY mutations: Genetic variations beyond MYCN and prognosis in neuroblastoma.
    Novak EM; Halley NS; Gimenez TM; Rangel-Santos A; Azambuja AM; Brumatti M; Pereira PL; Vince CS; Giorgi RR; Bendit I; Cristofani LM; Odone-Filho V
    Med Hypotheses; 2016 Dec; 97():22-25. PubMed ID: 27876123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment.
    Lambertz I; Kumps C; Claeys S; Lindner S; Beckers A; Janssens E; Carter DR; Cazes A; Cheung BB; De Mariano M; De Bondt A; De Brouwer S; Delattre O; Gibbons J; Janoueix-Lerosey I; Laureys G; Liang C; Marchall GM; Porcu M; Takita J; Trujillo DC; Van Den Wyngaert I; Van Roy N; Van Goethem A; Van Maerken T; Zabrocki P; Cools J; Schulte JH; Vialard J; Speleman F; De Preter K
    Clin Cancer Res; 2015 Jul; 21(14):3327-39. PubMed ID: 25805801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.